# Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir

> **NCT03631316** · NA · COMPLETED · sponsor: **Luis Eduardo Morales Buenrostro** · enrollment: 8 (actual)

## Conditions studied

- Kidney Transplantation
- Cytomegalovirus Infections
- Pharmacokinetics
- Therapeutic Equivalency

## Interventions

- **DRUG:** Generic Valganciclovir
- **DRUG:** Innovative Valganciclovir

## Key facts

- **NCT ID:** NCT03631316
- **Lead sponsor:** Luis Eduardo Morales Buenrostro
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2018-10-30
- **Final completion:** 2018-11-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631316, "Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03631316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*